Everything below concerns nuclear receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-09. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
High-velocity: Between 600 m/s (2,000 ft/s) and 1,000 m/s (3,500 ft/s) Usually caused by powerful assault or hunting rifles and usually cause Gustilo Type 3 wounds. The risk of infection is especially high due to the large area of injury and destroyed tissue. Bullets from handguns are sometimes less than 300 m/s (980 ft/s) but with modern pistol loads, they usually are slightly above 300 m/s (980 ft/s), while bullets from most modern rifles exceed 750 m/s (2,500 ft/s). One recently developed class of firearm projectiles is the hyper-velocity bullet, such cartridges are usually made for achieving such high speed, purpose-built in factories or made by amateurs. Examples of hyper velocity cartridges include the .220 Swift, .17 Remington and .17 Mach IV cartridges. The US military commonly uses 5.56mm bullets, which have a relatively low mass as compared with other bullets (2,6-4,0 grams); however, the speed of these bullets is relatively fast (approximately 850 m/s (2,800 ft/s), placing them in the high velocity category). As a result, they produce a larger amount of kinetic energy, which is transmitted to the tissues of the target. High energy transfer results in more tissue disruption, which plays a role in incapacitation, but other factors such as wound size and shot placement are also important.
Another group displayed, with a series of controls, that mixed droplet composition involving potassium iodide was detected accurately on the time scale of seconds with optimal voltage, velocity, and pH ranges. In addition to this, a more unique approach is developing within chronoamperometric readings, where magneto-fluidic systems have been created and the potential readings are measured in otherwise electro-inactive fluids by the dissolution of magnetic microparticles into the reagent. This method is enhanced into a digital microfluidic (DMF) setting, where gold and silver electrodes in junction with dissolved magnetic microparticles in the fluids replaced the typical fluorescence-based detection of droplets in the immunoassay of biomarker analytes. The above experiment by Shamsi et al, alludes to the main use for electrochemical detection in microfluidics; biosensing for various measurements such as enzyme kinetics and biological assays of many other types of cells. Increased control on the system is needed for these processes as with increasing flow rate, enzyme detection decreases. Though as an enzymatic reaction progresses, the amperometric reading will evolve as well, allowing for rapid monitoring of the kinetics. Also, specific surfactants can lack biocompatibility with the system, affecting the enzyme and skewing detection. The reaches of this application have even had effects in aquaculture and economics, as electrochemical sensing has been used to test the freshness of fish rapidly.
== History == Reslizumab was initially developed by Chuan-Chu Chou at Schering-Plough and was previously known as SCH-55700. In 1993, Chou and his group at Schering-Plough were granted the patent for the design, cloning and expression of the reslizumab drug. Ception Therapeutics acquired the drug and continued its development under the name CTx55700. In 2010, Ception Therapeutics was acquired by Cephalon for $250 million and the drug continued under development under the codename CEP-38072. In 2011, Teva Pharmaceuticals acquired Cephalon for $6.8 billion and continued the development of reslizumab.
== Early life and education == Doillon was born on 4 September 1982 in Neuilly-sur-Seine, France. She is the daughter of French writer/director Jacques Doillon and English actress/singer Jane Birkin. She has six brothers and sisters: Kate Barry and Charlotte Gainsbourg on her mother's side, and Lola Doillon, Lili Doillon, Lina Doillon and Lazare Doillon on her father's side. Doillon spent her school years between France and Saint Barthélemy until the age of 15, when she dropped out to become a full-time actress.
Sources: en.wikipedia.org
Such long, isolated helices can also be detected by other methods, such as dielectric relaxation, flow birefringence, and measurements of the diffusion constant. In stricter terms, these methods detect only the characteristic prolate (long cigar-like) hydrodynamic shape of a helix, or its large dipole moment.
Cold Mountain is an American opera in two acts and an epilogue, with music by Jennifer Higdon and the libretto by Gene Scheer, based on Charles Frazier's 1997 novel of the same name. The opera is a co-commission among Santa Fe Opera, Opera Philadelphia and the Minnesota Opera, in collaboration with North Carolina Opera. The opera received its world premiere at Santa Fe Opera on 1 August 2015. This production coincided with the 150th anniversary of the ending of the American Civil War. Opera Philadelphia gave its first performance of the opera, in a slightly revised form, on 5 February 2016. North Carolina Opera gave the opera its home state premiere on 28 September 2017. The Minnesota Opera staged the opera in 2018 as part of its New Works Initiative. The Virginia Opera also featured performances of the opera during February 2021 as part of its themed "Love is a Battlefield" 2020–2021 season.
== Universities == According to the 2020 QS World University Rankings, Chulalongkorn University (CU) was ranked 247th in the world and earned the top ranking in Thailand for the seventh consecutive year. Also ranked were Mahidol University (314th), and Chiang Mai University and Thammasat University (both in the 601–650 tranche), and four other Thai universities in the 801–1,000 tranche. The Times Higher Education Asia University Rankings 2018 ranked Mahidol University as the top Thai institution. It ranked 97 of some 350 universities (1=best; 350=lowest). King Mongkut's University of Technology Thonburi was ranked 116, Chulalongkorn University 164, and Suranaree University of Technology 168. Thailand had no other universities in the top 200. Chulalongkorn University was ranked number one in Thailand and 45th in Asia in 2016. Mahidol University was ranked the top Thai university among the top 200 Asian (including Middle Eastern) universities in 2016 by Times Higher Education Asia University Rankings 2016.
== Modern herbal medicine == The World Health Organization (WHO) estimates that 80 percent of the population of some Asian and African countries presently uses herbal medicine for some aspect of primary health care. Some prescription drugs have a basis as herbal remedies, including artemisinin, digoxin, quinine and taxanes.
Several immunodeficiency syndromes present clinical and laboratory characteristics of autoimmunity. The decreased ability of the immune system to clear infections in these patients may be responsible for causing autoimmunity through perpetual immune system activation. One example is common variable immunodeficiency (CVID), where multiple autoimmune diseases are seen, e.g., inflammatory bowel disease, autoimmune thrombocytopenia, and autoimmune thyroid disease. Familial hemophagocytic lymphohistiocytosis, an autosomal recessive primary immunodeficiency, is another example. Low blood levels of red blood cells, white blood cells, and platelets, rashes, lymph node enlargement, and enlargement of the liver and spleen are commonly seen in these patients. The presence of multiple uncleared viral infections due to a lack of perforin is thought to be responsible. In addition to chronic and/or recurrent infections, many autoimmune diseases, including arthritis, autoimmune hemolytic anemia, scleroderma, and type 1 diabetes, are also seen in X-linked agammaglobulinemia (XLA). Recurrent bacterial and fungal infections and chronic inflammation of the gut and lungs are seen in chronic granulomatous disease (CGD). CGD is caused by a decreased production of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase by neutrophils. Hypomorphic RAG mutations are seen in patients with midline granulomatous disease; an autoimmune disorder commonly occurring in patients with granulomatosis with polyangiitis and NK/T cell lymphomas.
Sources: en.wikipedia.org
The Cherokee Nation instigated a 10-year language preservation plan that involved developing new fluent speakers of the Cherokee language from childhood on up through school immersion programs, as well as a collaborative community effort to use the language at home. This plan was part of an ambitious goal so that in 50 years, 80% or more of the Cherokee people will be fluent in the language. The Cherokee Preservation Foundation has invested $3 million into opening schools, training teachers, and developing curricula for language education, as well as initiating community gatherings where the language can be used. Formed in 2006, the Kituwah Preservation & Education Program (KPEP) of the Eastern Band of Cherokee Indians, located on the Qualla Boundary in North Carolina, focuses on language immersion programs for children from birth to fifth grade. It is also developing cultural resources for the general public and community language programs to foster use of the Cherokee language among adults. A Cherokee language immersion school in Tahlequah, Oklahoma educates students from pre-school through eighth grade. Several universities offer Cherokee as a second language, including the University of Oklahoma, Northeastern State University, and Western Carolina University. Western Carolina University (WCU) has partnered with the federally recognized Eastern Band of Cherokee Indians (EBCI) to promote and restore the language through the school's Cherokee Studies program. It offers classes in and about the language and culture of the Cherokee Indians.
== Lineage == Constituted 5 July 1942 in the Army of the United States as the 2d Company, 1st Battalion, First Regiment, 1st Special Service Force, a combined Canadian-American organization Activated on 9 July 1942 at Fort William Henry Harrison, Montana Disbanded on 6 January 1945 in France Reconstituted on 15 April 1960 in the Regular Army; concurrently consolidated with Company B, 1st Ranger Infantry Battalion (activated 19 June 1942), and consolidated unit redesignated as Headquarters and Headquarters Company, 1st Special Forces Group, 1st Special Forces Consolidated on 30 September 1960 with Headquarters and Headquarters Company, 1st Special Forces Group (constituted 14 June 1957 in the Regular Army and activated 24 June 1957 in Japan), and the consolidated unit was designated as Headquarters and Headquarters Company, 1st Special Forces Group, 1st Special Forces (organic units concurrently constituted and activated 4 October 1960) Group inactivated 30 June 1974 at Fort Bragg, North Carolina Activated 1 September 1984 at Fort Lewis, Washington (Former Company B, 1st Ranger Infantry Battalion, withdrawn 3 February 1986, consolidated with Company N, 75th Infantry, and consolidated unit redesignated as Company N, 75th Ranger Regiment – hereafter separate lineage) Redesignated 1 October 2005 as the 1st Special Forces Group, 1st Special Forces Regiment
== Early life == Chain was born in Wilmington, Delaware, attended high school at Fork Union Military Academy and was a member of Fork Union Chapter of DeMolay International. He earned a Bachelor of Arts degree in history in 1956 and was awarded an honorary doctorate in humane letters in 1990, both from Denison University. While at Denison University, General Chain was a member of the Sigma Alpha Epsilon fraternity. In 1971 he graduated from the National War College and concurrently earned a master's degree in international affairs from George Washington University.
The American Society for Biochemistry and Molecular Biology publishes three research journals and a monthly magazine covering society news and activity updates. ASBMB journals are peer-reviewed and cover research in the fields of microbiology, molecular genetics, RNA-related research, proteomics, genomics, transcription, peptides, cell signaling, lipidomics, and systems biology. All articles are published online as "Papers in Press" upon acceptance. As of January 2021, all three ASBMB journals are fully open access.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.